Zobrazeno 1 - 10
of 12
pro vyhledávání: '"J F Heyse"'
Publikováno v:
Circulation. 97:946-952
Background —We determined the effect of incorporating the results of eight recently published trials of Hmg CoA reductase inhibitors (“statins”) on the conclusions from our previously published meta-analysis regarding the clinical benefit of ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a859ef6d6224a0730a542e0818e9d58
https://doi.org/10.1161/01.cir.97.10.946
https://doi.org/10.1161/01.cir.97.10.946
Autor:
G, Oster, G M, Borok, J, Menzin, J F, Heyse, R S, Epstein, V, Quinn, V, Benson, R J, Dudl, A M, Epstein
Publikováno v:
Archives of Internal Medicine. 156:731-739
The 1988 US National Cholesterol Education Program Expert Panel Report recommended initial treatment with niacin or bile acid sequestrants, followed by other agents if needed, to lower low-density lipoprotein cholesterol (LDL-C) levels in hypercholes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cb879ad2584ecb2535439901b70e54d
https://doi.org/10.1001/archinte.156.7.731
https://doi.org/10.1001/archinte.156.7.731
Publikováno v:
Circulation. 91:2274-2282
Background There has been a continuing debate about the overall benefit of cholesterol lowering. We performed a novel meta-analysis of all randomized trials of more than 2 years’ duration (n=35 trials) to describe how coronary-heart-disease (CHD),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9537771036b332768f10be2761fbe62c
https://doi.org/10.1161/01.cir.91.8.2274
https://doi.org/10.1161/01.cir.91.8.2274
Autor:
R A, Stine, J F, Heyse
Publikováno v:
Statistics in medicine. 20(2)
Kernel densities provide accurate non-parametric estimates of the overlapping coefficient or the proportion of similar responses (PSR) in two populations. Non-parametric estimates avoid strong assumptions on the shape of the populations, such as norm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a2408cfe208542aa1b4db2fe13a27ba9
https://pubmed.ncbi.nlm.nih.gov/11169598
https://pubmed.ncbi.nlm.nih.gov/11169598
Publikováno v:
American Journal of Epidemiology. 172:864-865
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfc7dd585fe87a2a22d8f83c7b86cb26
https://doi.org/10.1093/aje/kwq242
https://doi.org/10.1093/aje/kwq242
Autor:
J R, Cook, J F, Heyse
Publikováno v:
Statistics in medicine. 19(21)
Economic evaluations of medical technologies involve a consideration of both costs and clinical benefits, and an increasing number of clinical studies include a specific objective of assessing cost-effectiveness. These studies measure the trade-off b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::14e998ac9faff7beffd0f96135f1c990
https://pubmed.ncbi.nlm.nih.gov/11042628
https://pubmed.ncbi.nlm.nih.gov/11042628
Publikováno v:
The Urologic clinics of North America. 20(4)
Finasteride, a 5-alpha reductase inhibitor recently introduced for the treatment of symptomatic benign prostatic hyperplasia, reduces prostate size and decreases serum PSA concentration. To interpret PSA in men treated with finasteride, it is necessa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6341aa3826c0b9e41de0719570d2ea32
https://pubmed.ncbi.nlm.nih.gov/7505970
https://pubmed.ncbi.nlm.nih.gov/7505970
Publikováno v:
The Prostate. 22(1)
Finasteride is a specific 5-alpha-reductase inhibitor that has been shown to reduce prostate size and decrease serum levels of prostate specific antigen (PSA). Among men who received finasteride (5 mg/day) for 12 months in North American clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce4800b8d725fe435a0780f78ec8e396
https://pubmed.ncbi.nlm.nih.gov/7678930
https://pubmed.ncbi.nlm.nih.gov/7678930
Publikováno v:
European Respiratory Journal. 22:568.2-569
From the authors: We are in agreement with G.L. Braunstein's comment that it is important to discuss endpoints that are of clinical relevance to patients and to describe not just average values but results accounting for the entire population. His
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a44f3f2ee824d8865767a9b89ed74350
https://doi.org/10.1183/09031936.03.00048703a
https://doi.org/10.1183/09031936.03.00048703a
Publikováno v:
Journal of the National Cancer Institute. 72(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f6482c6478d2a7731b2a0cff11f89e87
https://pubmed.ncbi.nlm.nih.gov/6587143
https://pubmed.ncbi.nlm.nih.gov/6587143